SCHEMBL49790

SCHEMBL49790

CCCCOc1ccccc1[N]c1ccccc1OCCCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.58
CYP2C19 P33261 3/20 0.58
CYP2C9 P11712 2/20 0.58
TLR8 Q9NR97 2/20 0.46
LTA4H P09960 2/20 0.46
CYP19A1 P11511 1/20 0.45
KMT2A Q03164 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
NR1I2 O75469 1/20 0.44
LMNA P02545 1/20 0.44
CHRM2 P08172 1/20 0.44
CYP3A4 P08684 1/20 0.44
ADRA2A P08913 1/20 0.44
OPRK1 P41145 1/20 0.44
HTR2B P41595 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MCHR1 Q99705 1/20 0.42
PDE5A O76074 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10520469 0.90 CYP1A2 (0.46) CYP1A2CYP2C19CYP2C9TLR8KMT2A
1,2-Dibutoxybenzene SCHEMBL1226749 0.83 CYP1A2 (0.72) CYP1A2CYP2C19CYP2C9TLR8LTA4H
1,2-Dibutoxybenzene SCHEMBL29428927 0.83 CYP1A2 (0.72) CYP1A2CYP2C19CYP2C9TLR8LTA4H
SCHEMBL9362379 0.82 CYP1A2 (0.51) CYP1A2CYP2C19CYP2C9TLR8LTA4H
SCHEMBL49553 0.81 ALDH1A1 (0.54) CYP1A2CYP2C19TLR8KMT2AMAPT
1,2-Dibutoxybenzene SCHEMBL6236324 0.81 CYP1A2 (0.69) CYP1A2CYP2C19CYP2C9TLR8LTA4H
SCHEMBL30279573 0.80 CYP1A2 (0.50) CYP1A2CYP2C19CYP2C9TLR8LTA4H
1-Propoxy-2-Butoxybenzene SCHEMBL2846696 0.79 CYP1A2 (0.67) CYP1A2CYP2C19CYP2C9TLR8LTA4H
SCHEMBL27692693 0.78 LMNA (0.54) CYP1A2CYP2C19CYP2C9TLR8LTA4H
SCHEMBL11573790 0.78 CYP1A2 (0.47) CYP1A2CYP2C19CYP2C9TLR8LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129467-B2 Curing accelerating compound-silica composite material, method for producing curing accelerating compound-silica composite material, curing accelerator, curable resin composition, and electronic component device HITACHI CHEMICAL CO., LTD. (JP) 2012-03-06 US disclosed
US-8013052-B2 Curable resin, production method thereof, epoxy resin composition, and electronic device HITACHI CHEMICAL COMPANY, LTD. (JP) 2011-09-06 US disclosed
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE HITACHI CHEMICAL CO., LTD. (JP) 2009-03-05 US disclosed
US-20090023855-A1 NOVEL CURABLE RESIN, PRODUCTION METHOD THEREOF, EPOXY RESIN COMPOSITION, AND ELECTRONIC DEVICE RESONAC CORPORATION (JP) 2009-01-22 US disclosed
EP-0183191-B1 THIENYLTHIAZOLE COMPOUNDS Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1989-05-10 EP disclosed
US-4720493-A Thienylthiazole compounds YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1988-01-19 US disclosed
EP-0183191-A1 Thienylthiazole compounds Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1986-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE NCAPH, RAD51, H1-2 CYP1A2 2599/4885CYP2C19 3769/4885CYP2C9 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.